Biogen to discontinue Aduhelm


United States

Biogen Inc is to discontinue the development and commercialisation of Aduhelm (aducanumab), its monoclonal antibody treatment for Alzheimer’s disease in order to direct resources towards newer treatment types. Developed with Eisai Co Ltd, Aduhelm was given an accelerated approval by the US Food and Drug Administration on 7 June 2021 on the basis of data showing a reduction of beta-amyloid plaque in patients.